Acalabrutinib and Obinutuzumab for the Treatment of Previously Untreated Follicular Lymphoma or Other Indolent Non-Hodgkin Lymphomas — StellaPhase 2 — Testing in a larger group (up to a few hundred people) to further evaluate safety and begin to assess effectiveness.
Trial locations(1 site)
United States
Emory University Hospital/Winship Cancer Institute, Atlanta, Georgia Last updated February 2026